2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2023-9-1-0-62986Medicine (miscellaneous)<strong>Atrial fibrillation and its geriatric aspects: news of the last 5 years (review)</strong><br /> &nbsp;<strong>Atrial fibrillation and its geriatric aspects: news of the last 5 years (review)</strong><br /> &nbsp;BunovaSvetlana S.BunovaSvetlana S.ssbunova@mail.ruTimakovaArina Yu.TimakovaArina Yu.timakovaarinadr22@gmail.comSkirdenkoYulia P.SkirdenkoYulia P.julija-loseva1@yandex.ruNikolaevNikolay A.NikolaevNikolay A.niknik.67@mail.ruZhernakovaNina I.ZhernakovaNina I.zhernakova@bsu.edu.ruLebedevDmitry T.LebedevDmitry T.962612@bsu.edu.ruGorbunovaEvgeniya O.GorbunovaEvgeniya O.Skiagraph@gmail.com20239100

Background:&nbsp;The prevalence of atrial fibrillation in the modern world is constantly increasing. In most cases, this pathology occurs in elderly and senile people that makes it an important geriatric problem. Despite a large number of studies, there are many unresolved issues concerning pathogenesis and treatment of atrial fibrillation. The aim of the study:&nbsp;Analysis of current literature data about the etiology, pathogenesis, diagnosis and management of atrial fibrillation. Materials and methods:&nbsp;The scientific papers that were published in the open access in the databases of PubMed, Embase, Web of Science, Elibrary and Google Scholar were analyzed. Scientific articles that were mainly published in English since January 1, 2017 were chosen for further analysis. Their references to previously published works were considered. Literature sources were searched by the following keywords: atrial fibrillation, direct oral anticoagulants, catheter ablation, and genetics. In analyzing the literature, special attention was paid to systematic reviews and meta-analyses of research findings. Results:&nbsp;The review presents current data on the influence of inflammation and the state of the autonomic nervous system on the development of atrial fibrillation; much attention is paid to the role of genetic factors in its development.&nbsp;Attention is paid to the peculiarities of medication in the elderly. Attention is paid to the peculiarities of drug therapy in the elderly. The efficacy of various approaches to the treatment of atrial fibrillation is compared and attention is drawn to the possible prospects for further research in this field. Conclusion:&nbsp;The existing medication and surgical methods of atrial fibrillation treatment do not always achieve the desired results. The mortality rate of such patients remains high not only from complications of the natural course of the disease (thromboembolism), but also from complications of the ongoing treatment (hemorrhage). Despite significant progress in the study of atrial fibrillation, there is a need for additional research into the molecular mechanisms of this pathology, as well as the search for more effective and safe ways of anticoagulant and antiarrhythmic therapy.

Background:&nbsp;The prevalence of atrial fibrillation in the modern world is constantly increasing. In most cases, this pathology occurs in elderly and senile people that makes it an important geriatric problem. Despite a large number of studies, there are many unresolved issues concerning pathogenesis and treatment of atrial fibrillation. The aim of the study:&nbsp;Analysis of current literature data about the etiology, pathogenesis, diagnosis and management of atrial fibrillation. Materials and methods:&nbsp;The scientific papers that were published in the open access in the databases of PubMed, Embase, Web of Science, Elibrary and Google Scholar were analyzed. Scientific articles that were mainly published in English since January 1, 2017 were chosen for further analysis. Their references to previously published works were considered. Literature sources were searched by the following keywords: atrial fibrillation, direct oral anticoagulants, catheter ablation, and genetics. In analyzing the literature, special attention was paid to systematic reviews and meta-analyses of research findings. Results:&nbsp;The review presents current data on the influence of inflammation and the state of the autonomic nervous system on the development of atrial fibrillation; much attention is paid to the role of genetic factors in its development.&nbsp;Attention is paid to the peculiarities of medication in the elderly. Attention is paid to the peculiarities of drug therapy in the elderly. The efficacy of various approaches to the treatment of atrial fibrillation is compared and attention is drawn to the possible prospects for further research in this field. Conclusion:&nbsp;The existing medication and surgical methods of atrial fibrillation treatment do not always achieve the desired results. The mortality rate of such patients remains high not only from complications of the natural course of the disease (thromboembolism), but also from complications of the ongoing treatment (hemorrhage). Despite significant progress in the study of atrial fibrillation, there is a need for additional research into the molecular mechanisms of this pathology, as well as the search for more effective and safe ways of anticoagulant and antiarrhythmic therapy.

atrial fibrillationdirect oral anticoagulantscatheter ablationmiRNAelderly patientatrial fibrillationdirect oral anticoagulantscatheter ablationmiRNAelderly patientСписок литературыSilva A, Araujo J, Freitas R, et. al. Circulating MicroRNAs as Potential Biomarkers of Atrial Fibrillation. BioMed Research International. 2017;2017:7804763. DOI: https://doi.org/10.1155/2017/7804763Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021;42(5):373-498. DOI: https://doi.org/10.1093/eurheartj/ehaa612Kornej J, B&ouml;rschel C, Benjamin E, et al. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circulation Research. 2020;127(1):4-20. DOI: https://doi.org/10.1161/CIRCRESAHA.120.316340Calvo D, Filgueiras-Rama D, Jalife J. Mechanisms and drug development in atrial fibrillation. Pharmacological Reviews. 2018;70(3):505-525. DOI: https://doi.org/10.1124/pr.117.014183Scott L, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. International Journal of Cardiology. 2019;287:195-200. DOI: https://doi.org/10.1016/j.ijcard.2018.10.020Sagnard A, Hammache N, Sellal JM, et al. New Perspective in Atrial Fibrillation. Journal of Clinical Medicine. 2020;9(11):3713. DOI: https://doi.org/10.3390/jcm9113713Boos CJ. Infection and atrial fibrillation: Inflammation begets AF. European Heart Journal. 2020;41(10):1120-1122. DOI: https://doi.org/10.1093/eurheartj/ehz953Wu L, Emmens R, van Wezenbeek J, et al. Atrial inflammation in different atrial fibrillation subtypes and its relation with clinical risk factors. Clinical Research in Cardiology. 2020;109(10):1271-1281. DOI: https://doi.org/10.1007/s00392-020-01619-8Xu X, Zhao Z, Li G. The Therapeutic Potential of MicroRNAs in Atrial Fibrillation. Mediators of Inflammation. 2020;2020:3053520. DOI: https://doi.org/10.1155/2020/3053520Linz D, Elliot AD, Hohl M, et al. Role of autonomic nervous system in atrial fibrillation. International Journal of Cardiology. 2019;287:181-188. DOI: https://doi.org/10.1016/j.ijcard.2018.11.091Malik V, Mishima R, Elliott AD, et al. The &lsquo;Road&rsquo; to atrial fibrillation: The role of the cardiac autonomic nervous system. Journal of Atrial Fibrillation. 2020;13(1):74-80. DOI: https://doi.org/10.4022/jafib.2400Feghaly J, Zakka P, London B, et al. Genetics of atrial fibrillation. Journal of the American Heart Association. 2018;7(20):e009884. DOI: https://doi.org/10.1161/jaha.118.009884B&ouml;hm A, Vachalcova M, Snopek P, et al. Molecular mechanisms, diagnostic aspects and therapeutic opportunities of micro ribonucleic acids in atrial fibrillation. International Journal of Molecular Sciences.2020;21(8):2742. DOI: https://doi.org/10.3390/ijms21082742Nattel S, Heijman J, Zhou L, et al. Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. Circulation Research. 2020;127(1):51-72. DOI: https://doi.org/10.1161/circresaha.120.316363Liu Y, Tang R, Zhao Y, et al. Identification of key genes in atrial fibrillation using bioinformatics analysis. BMC Cardiovascular Disorders. 2020;20(1):363. DOI: https://doi.org/10.1186/s12872-020-01653-4Yang M, Wang Y, Xiong X, et al. SK4 calcium-activated potassium channels activated by sympathetic nerves enhances atrial fibrillation vulnerability in a canine model of acute stroke. Heliyon. 2020;6(5):e03928. DOI: https://doi.org/10.1016/j.heliyon.2020.e03928Dobrev D, Aguilar M, Heijman J et al. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nature Reviews Cardiology. 2019;16(7):417-436. DOI: https://doi.org/10.1038/s41569-019-0166-5Zhou D, Yang K, Hu J, et al. Noncoding RNAs in Atrial Fibrillation: Current Status and Prospect. Journal of Cardiovascular Pharmacology. 2020;75(1):10-17. DOI: https://doi.org/10.1097/fjc.0000000000000762Stepien E, Costa M, Kurc S, et al. The circulating non-coding RNA landscape for biomarker research: lessons and prospects from cardiovascular diseases. Acta Pharmacologica Sinica. 2018;39(7):1085-1099. DOI: https://doi.org/10.1038/aps.2018.35Salinas J, Lin H, Aparico HJ, et al. Whole blood microRNA expression associated with stroke: Results from the Framingham Heart Study. PLoS ONE. 2019;14(8):1-15. DOI: https://doi.org/10.1371/journal.pone.0219261Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.Grandi E, Dobrev D. Heijman J. Computational modeling: what does it tell us about atrial fibrillation therapy? International Journal of Cardiology. 2019;287:155-161. DOI: https://doi.org/10.1016/j.ijcard.2019.01.077Ramirez RJ, Takemoto Y, Martins RP, et al. Mechanisms by Which Ranolazine Terminates Paroxysmal but Not Persistent Atrial Fibrillation. Circulation Arrhythmia and Electrophysiology. 2019;12(10):e005557. DOI: https://doi.org/10.1161/circep.117.005557Ratte A, Wiedmann F, Kraft M, et al. Antiarrhythmic properties of ranolazine: Inhibition of atrial fibrillation associated TASK-1 potassium channels. Frontiers in Pharmacology. 2019;10:1367. DOI: https://doi.org/10.3389/fphar.2019.01367Keteyian SJ, Ehrman JK, Fuller B, et al. Exercise Testing and Exercise Rehabilitation for Patients with Atrial Fibrillation. Journal of Cardiopulmonary Rehabilitation and Prevention. 2019;39(2):65-72. DOI: https://doi.org/10.1097/hcr.0000000000000423Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. New England Journal of Medicine. 2021;384(4):305-315. DOI: https://doi.org/10.1056/nejmoa2029980Nakatani Y, Sakamoto T, Yamaguchi Y, et al. P-wave vector magnitude predicts recurrence of atrial fibrillation after catheter ablation in patients with persistent atrial fibrillation. Annals of Noninvasive Electrocardiology. 2019;24(5):e12646. DOI: https://doi.org/10.1111/anec.12646Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. Journal of the American College of Cardiology. 2020;75(25):3105-3118. DOI: https://doi.org/10.1016/j.jacc.2020.04.065Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine. 2020;383(14):1305-1316. DOI: https://doi.org/10.1056/nejmoa2019422Taniguchi N, Miyasaka Y, Suwa Y, et al. Heart failure in atrial fibrillation &ndash; An update on clinical and echocardiographic implications. Circulation Journal. 2020;84(8):1212-1217. DOI: https://doi.org/10.1253/circj.cj-20-0258Alberts M, Chen YW, Lin JH, et al. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin. Stroke. 2020;51(2):549-555. DOI: https://doi.org/10.1161/strokeaha.119.025554Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: The ARISTOPHANES study. Stroke. 2018;49(12):2933-2944. DOI: https://doi.org/10.1161/strokeaha.118.020232Bonde AN, Martinussen T, Lee CJ, et al. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. Circulation. Cardiovascular Quality and Outcomes. 2020;13(4):e006058. DOI: https://doi.org/10.1161/circoutcomes.119.006058Antza C, Doundoulakis I, Akrivos E, et al. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. Scandinavian Cardiovascular Journal. 2019;53(2):48-54. DOI: https://doi.org/10.1080/14017431.2019.1594353Yang WY, Du X, Jiang C, et al. The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: A report from the Chinese Atrial Fibrillation Registry study. Europace. 2020;22(1):90-99. DOI: https://doi.org/10.1093/europace/euz235Liang B, Zhao YX, Gu N. Discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation. Europace. 2020;22(7):1143-1144. DOI: https://doi.org/10.1093/europace/euaa038Skirdenko JP, Nikolayev NA. New approaches to individualized choice of oral anticoagulants in patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2018;14(1):58-64. Russian. DOI: https://doi.org/10.20996/1819-6446-2018-14-1-58-64Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: A population-based study. Heart. 2020;106(2):119-126. DOI: http://dx.doi.org/10.1136/heartjnl-2019-315307Hwang J, Han S, Bae HJ, et al. NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters? Thrombosis and Haemostasis. 2020;120(2):306-313. DOI: https://doi.org/10.1055/s-0039-1697954Ledwoch J, Duncker D. eHealth &ndash; Smart Devices revolutionieren die Kardiologiee Health &ndash; smart devices revolutionizing cardiology. Herzschrittmachertherapie und Elektrophysiologie. 2020;31(4):368-374. DOI: https://doi.org/10.1007/s00399-020-00700-zPerez MV, Mahaffey KW, Hedlin H, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine. 2019;381(20):1909-1917. DOI: https://doi.org/10.1056/nejmoa1901183Faust O, Ciaccio EJ, Acharya UR. A review of atrial fibrillation detection methods as a service. International Journal of Environmental Research and Public Health. 2020;17(9):3093. DOI: https://doi.org/10.3390/ijerph17093093Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. American Journal of Cardiology. 2013;112(8):1142-1147. DOI: https://doi.org/10.1016/j.amjcard.2013.05.063Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). European Heart Journal. 2014;35(47):3365-3376. DOI: https://doi.org/10.1093/eurheartj/ehu374Bo M, Grisoglio E, Brunetti E, et al. Oral anticoagulant therapy for older patients with atrial fibrillation: A review of current evidence. European Journal of Internal Medicine. 2017;41:18-27. DOI: https://doi.org/10.1016/j.ejim.2017.03.012Zathar Z, Karunatilleke A, Fawzy AM, et al. Atrial Fibrillation in Older People: Concepts and Controversies. Frontiers in Medicine. 2019;6:175. DOI: https://doi.org/10.3389/fmed.2019.00175Pilotto A, Gallina P, Copetti M, et al. Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. Journal of the American Geriatrics Society. 2016;64(7):1416-1424. DOI: https://doi.org/10.1111/jgs.14221Bo M, Li Puma F, Badinella Martini M, et al. Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. Aging Clinical and Experimental Research. 2017;29(3):491-497. DOI: https://doi.org/10.1007/s40520-016-0569-7Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a &ldquo;real-world&rdquo; observational study in the United States. International Journal of Clinical Practice. 2016;70(9):752-763. DOI: https://doi.org/10.1111/ijcp.12863Larsen TB, Skj&oslash;th F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. British Medical Journal. 2016;353:i3189. DOI: https://doi.org/10.1136/bmj.i3189Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2016;5(6):e003725. DOI: https://doi.org/10.1161/jaha.116.003725Kirchof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-2962. DOI: https://doi.org/10.1093/eurheartj/ehw210ф